Related Experiment Videos
Abdominal carcinoid tumours in Sheffield
H F Woods1, N D Bax, I Ainsworth
1University Department of Pharmacology and Therapeutics, Royal Hallamshire Hospital, Sheffield, UK.
Digestion
|January 1, 1990
Summary
Abdominal carcinoid tumors are rare, with the small bowel being the most common site. Treatment involves surgery and medication, with Sandostatin showing promise for symptom control and preventing carcinoid crisis.
Area of Science:
- Oncology
- Gastroenterology
Background:
- Carcinoid tumors are neuroendocrine neoplasms with varying incidence and presentation.
- Abdominal carcinoid tumors represent a significant subset, requiring specific diagnostic and therapeutic approaches.
Purpose of the Study:
- To discuss the incidence, clinical presentation, and treatment strategies for abdominal carcinoid tumors.
- To evaluate the role of Sandostatin in managing carcinoid syndrome and perioperative risks.
Main Methods:
- Retrospective analysis of carcinoid tumor cases in the Trent Region, UK.
- Review of presenting symptoms and signs in small bowel carcinoid cancer.
- Assessment of treatment outcomes with surgery, conventional drugs, and Sandostatin.
Main Results:
- Carcinoid tumor incidence in the Trent Region is 0.7 cases/100,000 population.
- Small bowel is the most frequent primary site (36%), followed by lung (22%) and appendix (13%).
- Common symptoms include diarrhea, pain, and flushing; Sandostatin is effective when other treatments fail or for prophylaxis.
Conclusions:
- Abdominal carcinoid tumors have a low incidence, with the small bowel being the most common primary site.
- A multimodal treatment approach including surgery, drug therapy, and potentially Sandostatin is crucial.
- Sandostatin demonstrates utility in managing refractory carcinoid syndrome and preventing carcinoid crisis during surgical procedures.